Concepedia

Greg Coffey

GC

Statistics

Publications

22

Citations

1.3K

H-Index

19

Active since

1999

Affiliations

Portola Pharmaceuticals (United States)(Current)

The University of Texas MD Anderson Cancer Center

University of California, San Francisco

Stanford University

University of Chicago

Greg Coffey is an author at Portola Pharmaceuticals (United States) specializing in pharmacology, medicine, and life sciences.

Publications per year

1999–2024

22

Publications

22

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

Julia Hoellenriegel, Greg Coffey, Uma Sinha et al. · Leukemia · 2012 · 141 citations

Medicine, Oncology, Pharmacology +14

Increases in Dopamine D3 Receptor Binding in Rats Receiving a Cocaine Challenge at Various Time Points after Cocaine Self-Administration: Implications for Cocaine-Seeking Behavior

Janet L. Neisewander, Rita A. Fuchs, Ly T.L. Tran-Nguyen et al. · Neuropsychopharmacology · 2004 · 118 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis

Greg Coffey, Francis DeGuzman, Mayuko Inagaki et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 117 citations

Medicine, Immunology, Pharmacology +17

SYK inhibition and response prediction in diffuse large B-cell lymphoma

Shuhua Cheng, Greg Coffey, Xu Hannah Zhang et al. · Blood · 2011 · 106 citations

Medicine, Cancer Biology, Oncology +14

The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer

Greg Coffey, Andreas Betz, Francis DeGuzman et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 91 citations

Medicine, Oncology, Pharmacology +15

1–5 of 22